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Abstract 
 
Background 
Knowledge about factors associated with provider ordering of appropriate testing is limited. 
 
Objective 
To determine physician factors correlated with ordering of recommended laboratory monitoring tests 
for high-risk medications, accounting for patient characteristics. 
 
Methods 
Analysis of the administrative claims and electronic medical records of patients prescribed a high-risk 
medication requiring laboratory monitoring in a large multispecialty group practice between January 1, 
2008 and December 31, 2008. The outcome is a physician order for each recommended laboratory test 
for each prescribed medication. Key predictor variables include physician characteristics, including age, 
gender, specialty training, years since completing training, and prescribing volume.  We used 
multivariable logistic regression to identify the independent association of physician and patient 
characteristics with ordering of laboratory tests to monitor medications after adjustment for potential 
confounders, taking into account clustering of drugs within patients and patients within providers. 
 
Results 
Physician orders for laboratory testing varied across drug-test pairs and ranged from 9% (Primidone–
Phenobarbital level) to 97% (Azathioprine–CBC) with 50% of drug-test pairs in the 85-91% ordered 
range. Failure to order a test was associated with lower provider prescribing volume for study drugs and 
whether the physician was a specialist (primary care providers were more likely to order tests than 
specialists). Patients with lower patient comorbidity burden and younger patients were less likely to 
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have appropriate tests ordered. Drug-test combinations with black box warnings were more likely to 
have tests ordered. 
 
Conclusions 
Interventions targeting providers should be addressed at those subgroups with the greatest potential 
for improvement: providers with lower frequencies of prescribing high-risk medications, and healthier 
and younger patients. Drug-test combinations with black box warnings have higher ordering rates, but 
many medications without such warnings also have evidence of harm, thus efforts to improve testing 
are necessary for all medications shown to be high-risk. 
